Molecular and Cytogenetic Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Study
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.290 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Ashutosh Kumar Verma und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Pediatric acute lymphoblastic leukemia (ALL) is a biologically diverse disease with multiple cytogenetic and molecular abnormalities that influence prognosis and treatment outcomes. Risk stratification based on these factors is essential for optimal therapy.
Objective
To assess the prognostic relevance of cytogenetic and molecular abnormalities in pediatric ALL and their association with treatment outcomes.
Methods
This retrospective study was conducted at Mahavir Cancer Sansthan, Patna, over one year and included 300 pediatric ALL patients. Cytogenetic evaluation was performed using karyotyping and FISH, while molecular analysis was carried out using RT-PCR to detect common fusion genes including ETV6-RUNX1, BCR-ABL1, and MLL rearrangements. Patients were categorized into standard, intermediate, and high-risk groups, and clinical outcomes were analyzed.
Results
High-risk cytogenetic abnormalities were observed in 28% of patients. Molecular analysis showed that ETV6-RUNX1 was the most common abnormality (24%), followed by BCR-ABL1 (7%) and MLL rearrangements (5%). Complete remission rates were significantly higher in standard-risk patients (93%) compared to high-risk patients (68%) (p < 0.001). Event-free survival was also lower in the high-risk group.
Conclusion
Both cytogenetic and molecular profiling are important for risk stratification in pediatric ALL and have a significant impact on treatment outcomes.
Zitieren
APA
Verma, A. K., Sajid, M., & Shrivastava, N. (2026). Molecular and Cytogenetic Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Study. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.290
Vancouver
Verma AK, Sajid M, Shrivastava N. Molecular and Cytogenetic Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.290
BibTeX
@article{Verma2026,
author = {Verma, Ashutosh Kumar and Sajid, Md and Shrivastava, Neha},
title = {Molecular and Cytogenetic Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Study},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.290}
}
EUVIMED